---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-23-000111"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2023-10-31T23:59:59+00:00"
generated_at: "2026-06-09T05:10:40.642022+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pfizer Q3 revenue $13.2B (-42% YoY), adjusted LPS $(0.17) on $5.6B write-off; reaffirms FY guidance

## Summary
- Q3 revenues $13.2B, down 41% operationally; non-COVID products grew 10% operationally.
- Reported diluted LPS $(0.42); adjusted diluted LPS $(0.17), including $5.6B non-cash inventory write-offs.
- Reaffirms FY2023 guidance: revenue $58-61B, adjusted EPS $1.45-$1.65; expects $1B cost savings in 2023.
- Comirnaty revenue down 70% operationally; Paxlovid down 97% operationally; Abrysvo contributed $375M.
- Launched enterprise cost realignment program targeting at least $3.5B annual net savings by end of 2024.

## SEC filing metadata
- accession: 0000078003-23-000111
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2023-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800323000111/0000078003-23-000111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800323000111/pfe-20231031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-23-000111
- JSON: https://secwatch.observer/filing/0000078003-23-000111.json
- Plain text: https://secwatch.observer/filing/0000078003-23-000111.txt

## Key facts
- Earnings Releases
  PFIZER INC reported the third quarter of 2023 results: revenue Revenues of $13.2 Billion, net income Reported (2) Net Income/(Loss) (2,382), EPS Reported (2) Diluted EPS/(LPS) (0.42). Guidance reaffirmed.
  - Period: the third quarter of 2023
  - Revenue: Revenues of $13.2 Billion
  - Net income: Reported (2) Net Income/(Loss) (2,382)
  - EPS: Reported (2) Diluted EPS/(LPS) (0.42)
  - Guidance: reaffirmed
  - Result: reported results
  source text: except as shall be expressly set forth by specific reference in such filing. --- EX-99 (EX-99) --- Pfizer Reports Third-Quarter 2023 Results ▪ Third-Quarter 2023 Revenues of $13.2 Billion – Expected Decline in Paxlovid and Comirnaty (1) Revenues Drove 41% Operational Decrease in Third-Quarter 2023 Revenues – Revenues for Pfizer’s Non-COVID Products Grew 10%
  evidence_url: https://www.sec.gov/Archives/edgar/data/78003/000007800323000111/0000078003-23-000111-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.